Trinity Biotech (TRIB) has commenced the commercial rollout in Brazil of its updated laboratory blood glucose monitoring solution, the next-generation HbA1c column system for its Premier Hb9210 platform, following receipt of local regulatory approval. This approval enables the introduction of the Company’s upgraded boronate affinity column system into one of the world’s largest diabetes markets. The enhanced Premier Hb9210 platform recently became the only HbA1c system worldwide to receive the prestigious International Federation of Clinical Chemistry Gold” classification for 2026, a designation recognising the highest levels of clinical accuracy, precision and traceability.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech Reports Major Technical Breakthroughs in Next-Generation CGM+ Platform
- Trinity Biotech Flags Lower Q4 2025 Revenue as It Accelerates Manufacturing Shift and Growth Plan
- Trinity Biotech announces advancements in CGM system development
- Trinity Biotech says continuing to focus on Comprehensive Transformation Plan
- Trinity Biotech sees Q4 revenue $11.5M-$12.5M vs. $15.9M last year